Wells Fargo’s Genetic Technologies Ltd. GENE Stock Holding History

Wells Fargo’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-130	Closed	-$312	–	7755
2023 Q4	$312	Buy	+130	New	+$431	﹤0.01%	6494
2023 Q3	–	Sell	-200	Closed	-$831	–	7717
2023 Q2	$831	Hold	200	–	–	﹤0.01%	6367
2023 Q1	$1.16K	Hold	200	–	–	﹤0.01%	6339
2022 Q4	$930	Hold	200	–	–	﹤0.01%	6208
2022 Q3	$1K	Hold	200	–	–	﹤0.01%	6515
2022 Q2	$1K	Buy	+200	New	+$1.45K	﹤0.01%	6663

Other funds holding GENE

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo's GENE Position: Q1 2024 in Review

Wells Fargo sold out of Genetic Technologies Ltd. (GENE) in Q1 2024, closing a stake of 130 shares — an estimated $312 sold.

Wells Fargo first reported a position in GENE in Q2 2022 and held it in 6 quarters. The position peaked at $1.16K in Q1 2023. 6 funds tracked by Wall St. Rank hold GENE as of Q1 2024.

Wells Fargo reported no remaining Genetic Technologies Ltd. position as of Q1 2024 after selling out during the quarter.
Wells Fargo sold 130 Genetic Technologies Ltd. shares in Q1 2024, an estimated $312.
Wells Fargo first reported a position in Genetic Technologies Ltd. in Q2 2022 and held it in 6 quarters.
Wells Fargo's Genetic Technologies Ltd. position peaked at $1.16K in Q1 2023.
6 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q1 2024.

Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.